Select Page

Beovu’s Failure to Warn About Risks Results in Litigation


Beovu is a medication that was manufactured by the company Novartis for the treatment of wet age-related macular degeneration or AMD. In 2019, the FDA approved the drug. In February 2020, the American Society of Retina Specialists issued a warning pertaining to potential side effects, where they cited 14 cases of retinal inflammation in patients that had undergone Beovu injections. These numbers later increased to cases of retinal vasculitis and retinal occlusion.

First Filed Claim

The first Beovu claim was filed in the US District Court for the District of Nebraska, alleging that Novartis and Alcon Research, LLC. failed to adequately warn users in the medical community about vision risks associated with the medication.

Legal Question

Currently, the legal issue facing the case is whether Novartis failed to adequately warn doctors and patients about the potential vision-related side effects directly caused by the Beovu injections.

Allegation Against Novartis

The primary allocation is that Novartis negligently misrepresented the safety of the injections in their label, and thus, if patients were to have known of the risks associated with Beovu, it is unlikely they would have been prescribed or used the drug. [1]

Research Studies and Side Effects  

Researchers with the American Society of Retina Specialists first raised concerns about vision risks associated with the medication last year. Also, according to the National Library of Medicine, there are several side effects from the drug that can lead to very serious complications[2] that require emergency medical treatment. These side effects are listed below:

  • Changes in vision
  • Pain or redness in the eye
  • Sensitivity to light
  • Bleeding in or around the eye
  • Vision affected by “floaters” and/or small specks
  • Hives, rash, redness, or itching
  • Swelling of the eyelid or the eye

Label Change

Because of the recent issues and side effects, some physicians have chosen to stop carrying or prescribing the injection drug in their inventories. Additionally, the FDA required that Novartis add a new warning label regarding the retinal vasculitis in June 2020. However, the risks are still not yet fully known.


Additionally, some of the injuries from the Beovu injection claims currently in litigation are:

  • Retinal vasculitis
  • Retinal artery occlusion
  • Occlusive retinal vasculitis
  • Vision loss
  • Blindness

If you or a loved one have been injured by Beovu, please contact us at the Michael Brady Lynch Firm at 888-585-5970. The consultation is completely free and confidential.



What is an Offer in Compromise?

What is an Offer in Compromise?

Offer in Compromise An offer in compromise occurs when the taxpayer has an outstanding balance with the IRS and needs a tax attorney to represent them on their behalf. The rate of acceptance from...

read more
Sex Abuse and The Boy Scouts of America

Sex Abuse and The Boy Scouts of America

Many youth organizations formed for the betterment of children have been publicly and legally scrutinized in recent years for allegations of perpetrating sexual assault and abuse. They have failed...

read more
The Adverse Effects of Paraquat (Part 3)

The Adverse Effects of Paraquat (Part 3)

History of Paraquat  Paraquat was first produced for commercial purposes in 1961.[1] In the United States, Paraquat is only available to be used by licensed applicators for commercial purposes. That...

read more
The Damages of Labor Trafficking

The Damages of Labor Trafficking

Labor Trafficking is “The recruitment, harboring, transportation, provision, or obtaining of a person for labor or services, through the use of force, fraud, or coercion for the purpose of...

read more
The Adverse Effects of Paraquat (Part 2)

The Adverse Effects of Paraquat (Part 2)

Paraquat, also known as Methyl Viologen, is a highly toxic and fast-acting chemical formula herbicide used primarily for weed and grass control. It was manufactured and introduced in 1961 by the...

read more
What Our Clients Are Saying